FORM 3A - Director/Chief Executive Notice - Interests in Shares of Listed Corporation
 
Form Serial Number: DA20241218E00135
(Amendment to DA20241121E00304)
1. Date of relevant event: 20/11/2024
(dd/mm/yyyy)
2. Date when director became aware of the relevant event/ interest in the shares (if later):
(dd/mm/yyyy)
3. Stock code: 06998
4. Name of listed corporation: Genor Biopharma Holdings Ltd. - B 
5. Class of shares: Ordinary Shares 
6. Number of issued shares in class: 520,291,899
7. Name of director (English) as printed on HKID Card/Passport:
(Surname) Weng
(Other names) Cheng Yi
10. Name of director (Chinese): 翁承毅 
11. Chinese Character Code as printed on HKID Card:
 
24. Details of relevant event:
  Brief description of relevant event Capacity in which shares were/are held Number of shares bought/sold or involved Currency of transaction On Exchange Off Exchange
Before relevant event After relevant event Highest price (per share) Average price (per share) Average consideration (per share) Consideration code
Long position 
1711Miscellaneous
Other (you must briefly describe the relevant event in the Supplementary Information box)
 
2101Beneficial owner
 
2101Beneficial owner
 		 1,522,500         
 
Short position 
 
 
 		            
 
25. Total shares in listed corporation immediately before the relevant event:
 Total number of sharesPercentage figure (%)
Long position1,522,5000.29
 
26. Total shares in listed corporation immediately after the relevant event:
 Total number of sharesPercentage figure (%)
Long position1,522,5000.29
 
27. Capacity in which interests disclosed in Box 26 are held:
Code describing capacityNumber of shares
2101Beneficial owner
Long position1,522,500
 
28. Further information in derivative interests in listed corporation :
Derivatives code Exercise period (dd/mm/yyyy) Consideration - if derivatives granted by listed corporation Number of shares
  BeginsEndsCurrencyPrice for grantCurrencyExercise priceCurrencyPrice on assignment 
Long position
4105Unlisted derivatives - Physically settled
16/09/201916/09/2029USD0USD2.000  220,000
Long position
4105Unlisted derivatives - Physically settled
16/04/202016/04/2030USD0USD2.000  120,000
Long position
4105Unlisted derivatives - Physically settled
31/08/202331/08/2033HKD0HKD1.500  600,000
Long position
4105Unlisted derivatives - Physically settled
31/08/202331/08/2033HKD0HKD1.500  210,000
 
29. Further information in relation to interests of children under 18 and/or spouse:
Child/SpouseName of child/spouseNumber of shares
 
 
30. Further information in relation to interests of corporations controlled by Director:
Name of controlled corporationAddress and place of incorporationName of controlling person% controlDirect interest (Y/N)Number of shares
   
 
31. Further information in relation to interests held by Director jointly with another person:
Name of joint shareholderAddressNumber of shares
 
 
32. Further information from a director who is a trustee, or beneficiary of a trust, or a person who has set up a Discretionary Trust:
Names of TrustAddressStatus codeNumber of shares
  
 
33. Further information from a party to an agreement under Section 317 (Please see Notes for further information required):
Names of other partiesAddressNumber of shares
 
Total number of shares in which a director is interested under sections 317 and 318
 
34. Supplementary information: Mr. Weng was holding 372,500 shares as at 20 November 2024 and is entitled to receive up to 340,000 shares and 600,000 shares pursuant to the exercise of options under the Pre-IPO Share Option Plan and Post-IPO Share Option Plan respectively, and is entitled to receive up to 210,000 restricted share units ("RSUs") (each RSU represents 1 share) pursuant to the vesting of RSUs under the 2021 RSU Plan, subject to the fulfillment of conditions of these options and RSUs.
35. Log/Serial Number of the previous form: DA20241121E00304
36. Number of concert party document(s) under section 317 attached/uploaded: 0
Date of filing this Form 3A: 18/12/2024
(dd/mm/yyyy)